Innate Pharma Reports Third Quarter Financial Results
14 Novembre 2022 - 07:00AM
- Preliminary data from ongoing Phase 2 TELLOMAK trial of
lacutamab demonstrated clinical activity in mycosis fungoides,
presented at EORTC-CLTG annual meeting
- Preliminary Sezary syndrome lacutamab Phase 2 data to be
presented at ASH 2022 Annual Congress
- Innovative ANKET™ pipeline will be on display
at ASH 2022 Annual Congress
- Cash position of €151.4 million1 as of 30 September 2022,
with anticipated cash runway into H2 2024
- Conference call to be held today at 2:00 p.m. CET / 8:00
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)
(“Innate” or the “Company”) today announced its
revenues and cash position for the first nine months of 2022.
“Innate’s strong financial position, innovative science and
strategic collaborations enable us to progress a focused pipeline
of antibodies, including several potentially first-in-class
clinical and preclinical candidates, in cancers with high unmet
medical need.” said Mondher Mahjoubi, Chief Executive Officer of
Innate Pharma. “We are pleased to see that lacutamab continues
to show clinical activity in mycosis fungoides. We look forward to
sharing data from the Phase 2 TELLOMAK trial for lacutamab in
Sézary syndrome at ASH, as well as shining the spotlight on our
proprietary ANKET™ platform, which demonstrates an important role
in activating an anti-tumor response. Our third strategic pillar
continues to advance, as part of our collaboration with AstraZeneca
the PACIFIC-9 Phase 3 study of monalizumab in the early non-small
cell lung cancer setting.”
Webcast and conference call will be held today at 2:00pm CET
The live webcast will be available at the
following link: https://events.q4inc.com/attendee/306131452
Participants may also join via telephone by registering in
advance of the event at:
https://registrations.events/direct/Q4E60139. Upon registration,
participants will be provided with dial-in numbers, a direct event
passcode and a unique registrant ID that they may use 10 minutes
prior to the event start to access the call.
This information can also be found on the Investors section of
the Innate Pharma website, www.innate-pharma.com. A replay of the
webcast will be available on the Company website for 90 days
following the event.
- Preliminary results from the Phase 2 TELLOMAK study were
presented at the EORTC-CLTG (European Organisation for Research and
Treatment of Cancer - Cutaneous Lymphoma Tumours Group) 2022
meeting on 23 September, confirming clinical activity and favorable
safety profile of lacutamab in patients with mycosis fungoides who
express KIR3DL2 and who were previously treated with at least two
lines of systemic therapy. Results showed that lacutamab produced a
global objective response rate (ORR) of 28.6% (95% confidence
interval [CI], 13.8-50.0) in the KIR3DL2-expressing MF patients
(n=21), including 2 complete responses and 4 partial
- The Company announced that it will report preliminary data from
the Phase 2 TELLOMAK study in Sézary syndrome at the ASH (American
Society of Hematology) 2022 Annual Congress on 10 December. The ASH
abstract states that the preliminary data demonstrate that
lacutamab showed clinical activity and a favorable safety profile.
In the heavily pre-treated post-mogamulizumab patient population
with an average of six prior lines of therapy, in the Intention to
treat population (ITT) population, the global confirmed ORR was
21.6% (8/37). Confirmed ORR in the skin was 35.1% (13/37) and
confirmed ORR in the blood was 37.8% (14/37). Additional data will
be presented at the ASH 2022 Annual Congress.
- On 11 September, at the ESMO 2022 conference, the Company
presented a poster on the ongoing lacutamab Phase 1b trial design
in monotherapy in peripheral T-cell lymphoma (PTCL).
- Two clinical trials are underway evaluating lacutamab in
patients with KIR3DL2-expressing, relapsed/refractory PTCL:
- Phase 1b trial: a Company-sponsored Phase 1b clinical trial to
evaluate lacutamab as a monotherapy in patients with
KIR3DL2-expressing relapsed PTCL.
- Phase 2 KILT (anti-KIR in T Cell Lymphoma) trial: The Lymphoma
Study Association (LYSA) investigator-sponsored, randomized trial
to evaluate lacutamab in combination with chemotherapy GEMOX
(gemcitabine in combination with oxaliplatin) versus GEMOX alone in
patients with KIR3DL2-expressing relapsed/refractory PTCL.
ANKET™ (Antibody-based NK cell Engager
- An 18 October edition of Cell Reports Medicine described the
development of Innate’s fit-for-purpose ANKET™ antibody-based
tetra-specific molecule to harness the antitumor functions of NK
cells, boosting their capacity to proliferate, to accumulate at the
tumor site and to kill tumor cells.
- Progress continues toward investigational new drug (IND) filing
in 2023 for the CD20 targeted tetra-specific ANKET™, IPH6501.
- Sanofi will present two posters on SAR’579/IPH6101 and
SAR’514/IPH6401 at the ASH 2022 Annual Congress on the 11 and 12
- An open-label, first-in-human, dose-escalation study of
SAR443579 administered as single agent by intravenous infusion in
patients with relapsed or refractory acute myeloid leukemia (R/R
AML), B-cell acute lymphoblastic leukemia (B-ALL) or high-risk
- The Novel Trifunctional Anti-BCMA NK Cell Engager SAR’514 Has
Potent in-Vitro and in-Vivo Anti-Myeloma Effect through Dual NK
- The Phase 1/2 clinical trial by Sanofi continues, evaluating
IPH6101/SAR’579, the first NKp46/CD16-based CD123-targeted ANKET™
NK cell engager, in patients with relapsed or refractory acute
myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia
(B-ALL) or high-risk myelodysplastic syndrome (HR-MDS).
- It was previously announced that Sanofi had made the decision
to progress IPH6401/SAR’514 into investigational new drug
(IND)-enabling studies. IPH6401/SAR’514 is a BCMA-targeting NK cell
engager using Sanofi’s proprietary CROSSODILE® multi-functional
platform, which comprises the Cross-Over-Dual-Variable-Domain
(CODV) format. It induces a dual targeting of the NK activating
receptors, NKp46 and CD16, for an optimized NK cell activation,
based on Innate’s ANKET™ proprietary platform.
Monalizumab (anti-NKG2A antibody),
partnered with AstraZeneca:
- Innate continues to see progress for monalizumab in the early
non-small cell lung cancer setting, with the ongoing Phase 3
PACIFIC-9 study run by AstraZeneca.
- On 12 September at the European Society for Medical Oncology
(ESMO) 2022 congress, AstraZeneca presented an oral presentation on
the Phase 2 NeoCOAST study assessing the safety and efficacy of
neoadjuvant durvalumab in combination with chemotherapy and
oleclumab (AstraZeneca’s anti-CD73) or monalizumab and adjuvant
treatment in patients with resectable, early-stage NSCLC.
- On 1 August, Innate announced that a planned futility interim
analysis of the Phase 3 INTERLINK-1 study sponsored by AstraZeneca
did not meet a pre-defined threshold for efficacy. The company
announced that, based on the result and the recommendation of an
Independent Data Monitoring Committee, the study was to be
discontinued. There were no new safety findings. AstraZeneca plan
to share the data in due course. The INTERLINK-1 study, evaluated
monalizumab in combination with cetuximab vs. cetuximab in patients
with recurrent or metastatic squamous cell carcinoma of the head
and neck who have been previously treated with platinum-based
chemotherapy and PD-(L)1 inhibitors.
IPH5201 (anti-CD39), partnered with
- The previously announced Phase 2 clinical trial conducted by
Innate in lung cancer for IPH5201, an anti-CD39 blocking monoclonal
antibody developed in collaboration with AstraZeneca, is in
planning. The Company will present a poster of preclinical data
supporting the rationale for the clinical trial at the 2022 ESMO
Immuno-Oncology (IO) Annual Congress in December.
- AstraZeneca will present a poster entitled “IPH5201 as
Monotherapy or in Combination with Durvalumab in Advanced Solid
Tumours” at the 2022 ESMO IO Annual Congress in December.
- The investigator-sponsored Phase 1 trial of IPH5301 (CHANCES),
in collaboration with Institut Paoli-Calmettes is ongoing. The
trial will be conducted in two parts, Part 1, the dose escalation,
followed by a Part 2 safety expansion study cohort. Part 2 will
evaluate IPH5301 in combination with chemotherapy and trastuzumab
in HER2+ cancer patients. The design of the Phase 1 study will be
highlighted at the ESMO IO congress in December.
- On May 03, Innate announced the commencement of an
At-The-Market (ATM) program, pursuant to which it may, from time to
time, offer and sell to eligible investors a total gross amount of
up to $75 million American Depositary Shares (“ADS”). Each ADS
representing one ordinary share of Innate. As of September 30,
2022, the balance available under our May 2022 sales agreement
remains at $75 million.
- Cash, cash equivalents and financial assets of the Company
amounted to €151.4 million as of September 30, 2022. At the same
date, financial liabilities amounted to €43.1 million.
- Revenues for the first nine months of 2022 amounted to €44.3
million (€10.3 million for the same period in 2021). For the
nine-month period, ended September 30, 2022, revenue from
collaboration and licensing agreements mainly results from the
spreading of the payments received under our agreements with
AstraZeneca and Sanofi.
About Innate Pharma:
Innate Pharma S.A. is a global, clinical-stage oncology-focused
biotech company dedicated to improving treatment and clinical
outcomes for patients through therapeutic antibodies that harness
the immune system to fight cancer.
Innate Pharma’s broad pipeline of antibodies includes several
potentially first-in-class clinical and preclinical candidates in
cancers with high unmet medical need.
Innate is a pioneer in the understanding of Natural Killer cell
biology and has expanded its expertise in the tumor
microenvironment and tumor-antigens, as well as antibody
engineering. This innovative approach has resulted in a diversified
proprietary portfolio and major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb, Novo
Nordisk A/S, Sanofi, and a multi-products collaboration with
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com
Information about Innate Pharma shares:
Euronext: IPH Nasdaq: IPHA
Disclaimer on forward-looking information and risk
This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities
Litigation Reform Act of 1995. The use of certain words, including
“believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s commercialization efforts and the Company’s continued
ability to raise capital to fund its development. For an additional
discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque")
section of the Universal Registration Document filed with the
French Financial Markets Authority (“AMF”), which is available on
the AMF website http://www.amf-france.org or on Innate Pharma’s
website, and public filings and reports filed with the U.S.
Securities and Exchange Commission (“SEC”), including the Company’s
Annual Report on Form 20-F for the year ended December 31, 2021,
and subsequent filings and reports filed with the AMF or SEC, or
otherwise made public, by the Company.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
1 Including short term investments (€21.6 million) and
non-current financial instruments (€34.3 million).
version on businesswire.com: https://www.businesswire.com/news/home/20221113005104/en/
For additional information:
Innate Pharma Henry Wheeler Tel.: +33 (0)4 84 90
32 88 Henry.email@example.com
NewCap Arthur Rouillé Tel.: +33 (0)1 44 71 00 15
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Fév 2023 à Mar 2023
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Mar 2022 à Mar 2023